This is a 24-month, observational study of 100 participants with Limb Girdle Muscular Dystrophy type R1, also known as CAPN3.
- Investigator
- Carla Zingariello
- Status
- Accepting Candidates
- Ages
- 12 Years - 50 Years
- Sexes
- All
Neuromuscular Medicine Specialist, Pediatric Neurologist, Pediatric Neuromuscular Rehabilitation Specialist
Dr. Zingariello is actively involved in research in her field. She is currently the Principal Investigator on a muscular dystrophy grant from CDC to University of Florida. She also serves as PI for a Limb Girdle muscular dystrophy clinical trial. She has a Children鈥檚 Miracle Network grant to investigate factors contributing to delays in diagnosis of juvenile myasthenia gravis and spinal muscular atrophy. She additionally serves as a sub-Investigator on multiple gene therapy clinical trials for Duchenne Muscular Dystrophy.
This is a 24-month, observational study of 100 participants with Limb Girdle Muscular Dystrophy type R1, also known as CAPN3.
This study will evaluate the safety and efficacy of long-term administration of BBP-418 in patients with LGMD2I/R9. The study will include patients ages 12 to 60, consistent with the existing preclinical toxicology profile. This will encompass the鈥�
12 publications
2022
Annals of clinical and translational neurology
鈥�2022
Pediatric neurology
鈥�2021
Child neurology open
鈥�2020
Pediatric neurology
鈥�2019
Neurology. Clinical practice
鈥�